United Therapeutics (NASDAQ:UTHR) CEO Sells $4,647,400.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $489.20, for a total value of $4,647,400.00. Following the transaction, the chief executive officer owned 324,443 shares of the company’s stock, valued at $158,717,515.60. The trade was a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

United Therapeutics Price Performance

Shares of UTHR stock opened at $503.86 on Friday. The stock has a market cap of $21.61 billion, a PE ratio of 18.03, a price-to-earnings-growth ratio of 2.53 and a beta of 0.56. The stock has a 50-day moving average of $522.08 and a 200-day moving average of $540.60. United Therapeutics Corporation has a one year low of $395.00 and a one year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping the consensus estimate of $6.86 by $0.41. The business had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. United Therapeutics’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter last year, the firm earned $6.41 EPS. As a group, research analysts anticipate that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

Analyst Ratings Changes

UTHR has been the topic of a number of recent analyst reports. Morgan Stanley set a $515.00 price target on shares of United Therapeutics in a research report on Thursday, August 6th. Royal Bank Of Canada lowered their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Weiss Ratings downgraded United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, August 27th. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Finally, Bank of America decreased their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $646.00.

Institutional Investors Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of UTHR. Geneos Wealth Management Inc. grew its stake in shares of United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 85 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in shares of United Therapeutics by 18.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 70 shares in the last quarter. Jump Financial LLC bought a new stake in shares of United Therapeutics in the second quarter worth $277,000. Cerity Partners LLC boosted its holdings in United Therapeutics by 77.3% during the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock worth $3,691,000 after purchasing an additional 5,600 shares during the last quarter. Finally, Bank of Nova Scotia boosted its holdings in United Therapeutics by 6.9% during the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock worth $468,000 after purchasing an additional 105 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.